These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 23616968

  • 1. Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance.
    Porhownik NR, Myers R, Bshouty Z.
    Can Respir J; 2013; 20(2):111-5. PubMed ID: 23616968
    [Abstract] [Full Text] [Related]

  • 2. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D.
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [Abstract] [Full Text] [Related]

  • 3. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM.
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [Abstract] [Full Text] [Related]

  • 5. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.
    Porhownik NR, Al-Sharif H, Bshouty Z.
    Can Respir J; 2008 Mar; 15(8):427-30. PubMed ID: 19107243
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.
    Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J.
    Eur Respir J; 2004 Dec; 24(6):1007-10. PubMed ID: 15572546
    [Abstract] [Full Text] [Related]

  • 7. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
    Seyfarth HJ, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J.
    Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
    [Abstract] [Full Text] [Related]

  • 8. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
    Douwes JM, Roofthooft MT, Van Loon RL, Ploegstra MJ, Bartelds B, Hillege HL, Berger RM.
    Heart; 2014 Feb; 100(3):224-30. PubMed ID: 24390161
    [Abstract] [Full Text] [Related]

  • 9. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galiè N.
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [Abstract] [Full Text] [Related]

  • 10. "Treat-to-target" in pulmonary arterial hypertension and the use of extracorporeal membrane oxygenation as a bridge to transplantation.
    Hoeper MM.
    Eur Respir Rev; 2011 Dec; 20(122):297-300. PubMed ID: 22130824
    [No Abstract] [Full Text] [Related]

  • 11. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [Abstract] [Full Text] [Related]

  • 12. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension.
    He B, Zhang F, Li X, Tang C, Lin G, Du J, Jin H.
    Circ J; 2010 Jul; 74(7):1458-64. PubMed ID: 20519876
    [Abstract] [Full Text] [Related]

  • 13. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.
    Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F.
    J Am Coll Cardiol; 2003 Jul 02; 42(1):158-64. PubMed ID: 12849677
    [Abstract] [Full Text] [Related]

  • 14. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.
    Catapano-Minotti G, Corsonello A, Guadalupi G, Spani R, Antonelli-Incalzi R.
    Intern Med; 2008 Jul 02; 47(6):511-3. PubMed ID: 18344637
    [Abstract] [Full Text] [Related]

  • 15. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
    Han X, Zhang Y, Dong L, Fang L, Chai Y, Niu M, Yu Y, Liu L, Yang X, Qu S, Li S.
    Respir Care; 2017 Apr 02; 62(4):489-496. PubMed ID: 28119496
    [Abstract] [Full Text] [Related]

  • 16. [Drug combination treatment for pulmonary arterial hypertension].
    Ghofrani HA, Hoeper MM.
    Dtsch Med Wochenschr; 2006 Dec 08; 131(49 Suppl 9):S330-3. PubMed ID: 17139600
    [Abstract] [Full Text] [Related]

  • 17. Pulmonary arterial hypertension: combination therapy in the modern management era.
    Sitbon O.
    Eur Respir Rev; 2010 Dec 08; 19(118):348-9. PubMed ID: 21119195
    [No Abstract] [Full Text] [Related]

  • 18. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.
    J Am Coll Cardiol; 2010 May 04; 55(18):1915-22. PubMed ID: 20430262
    [Abstract] [Full Text] [Related]

  • 19. Combination drug therapy in the management of pulmonary arterial hypertension.
    Kayser SR.
    Prog Cardiovasc Nurs; 2005 May 04; 20(4):177-82. PubMed ID: 16276142
    [No Abstract] [Full Text] [Related]

  • 20. Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller.
    Kamata Y, Iwamoto M, Minota S.
    Lupus; 2007 May 04; 16(11):901-3. PubMed ID: 17971364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.